 |
160 Products |  |
813 Diseases | | 160 Products |
|
1586 Trials |  |
77739 News |  |
| «12...56789101112131415...897898» |
- | Prolia (denosumab) / Amgen
Journal, Checkpoint inhibition: Bone metastases diminish extraosseous response to checkpoint blockade immunotherapy through osteopontin-producing osteoclasts. (Pubmed Central) - Apr 27, 2025
Both the mode of action and therapeutic benefit were validated in clinical cohorts with the ?RANKL-ICB combinatory regimen. These findings establish bone as a specific immunoregulatory organ exploited by tumor metastasis and suggest osteoclastogenesis as a promising target to improve ICB prognosis in patients with bone metastasis.
- | Lumakras (sotorasib) / Amgen
Journal: Successful Management of Acquired von Willebrand Syndrome Associated with Monoclonal Gammopathy of Undetermined Significance After Sotorasib Treatment in a Patient with Non-Small-Cell Lung Carcinoma. (Pubmed Central) - Apr 27, 2025
By inhibiting KRAS in stromal cells and osteoclasts, sotorasib may have disrupted the supportive niche necessary for malignant plasma cell survival, resulting in a reduction in the monoclonal spike. Unfortunately, the patient eventually succumbed to carcinogenic pleurisy.
- | Nplate (romiplostim) / Amgen, Doptelet (avatrombopag) / SOBI, Promacta (eltrombopag) / Novartis
Journal, HEOR, Cost-effectiveness: The Cost-Effectiveness of Avatrombopag Versus Eltrombopag and Romiplostim in the Treatment of Patients with Immune Thrombocytopenia in the UK. (Pubmed Central) - Apr 27, 2025
Unfortunately, the patient eventually succumbed to carcinogenic pleurisy. Avatrombopag is a cost-effective treatment compared with romiplostim and eltrombopag for the second-line treatment of adults with ITP from the perspective of the UK NHS.
- | imatinib / Generic mfg., Stivarga (regorafenib) / Bayer, sunitinib / Generic mfg.
Journal: Effects of first?line therapies in patients with locally advanced gastrointestinal stromal tumors with KIT and PDGFR? gene mutations: A single?center study. (Pubmed Central) - Apr 27, 2025
The present study elucidated the effects of first-line therapy on LAGISTs with genetic mutations, underscoring the effectiveness of imatinib treatment and the value of continual patient monitoring. Additional studies with long-term follow-up are required to evaluate treatment outcomes.
- | Aimovig (erenumab-aooe) / Amgen, Novartis
Biomarker, Journal: Plasma SuPAR and therapeutic response to erenumab in migraine: a REFORM study. (Pubmed Central) - Apr 27, 2025
P4
Plasma suPAR concentrations remained stable, even among participants with aura. These findings suggest that systemic low-grade inflammation, as measured by suPAR, does not influence treatment efficacy.
- || P1/2 data, Retrospective data, Review, Journal, Monotherapy: KRAS G12C inhibitors as monotherapy or in combination for metastatic colorectal cancer: A proportion and comparative meta-analysis of efficacy and toxicity from phase I-II-III trials. (Pubmed Central) - Apr 27, 2025
This analysis suggests that KRAS-G12C inhibitors in combination with anti-EGFR agents may provide a doubled ORR and 1.5-month PFS benefit compared to monotherapy in previously treated mCRC patients, but with a doubled grade 3-4 TRAEs, including skin toxicities, paronychia, and hypomagnesemia. Treatment preferences should be individualized in these highly pretreated patients.
- | omecamtiv mecarbil (AMG 423) / Amgen, Servier
Journal: Estimation of Active Tension in Cardiac Microtissues by Solving a PDE-Constrained Optimization Problem. (Pubmed Central) - Apr 27, 2025
Next, we employed the procedure to evaluate active tension changes in drug escalation studies of the inotropes omecamtiv mecarbil and Bay K8644...The computational framework presented here allows for spatiotemporal estimation of active tension in cardiac microtissues based on optical measurements. In the future, such methodologies might develop into valuable tools in drug development protocols.
- | Aimovig (erenumab-aooe) / Amgen, Novartis
Journal: Clinical predictors for efficacy of erenumab for migraine: a Registry for Migraine (REFORM) study. (Pubmed Central) - Apr 27, 2025
Moreover, patients with a more severe clinical phenotype were more likely to respond later. Prediction of treatment responses might be improved by incorporating machine learning models and multimodal biomarkers, facilitating a shift towards personalized medicine.
- || Review, Journal, IO biomarker: Bispecific antibodies in immunotherapy for acute leukemia: latest updates from the 66th annual meeting of the American society of hematology, 2024. (Pubmed Central) - Apr 27, 2025
The meeting underscored the transformative potential of BsAbs, especially in ALL-focused trials, with ongoing research aiming to evaluate their safety and efficacy in broader patient populations and combination regimens. This summary highlights the latest progress in BsAb-based immunotherapy presented at the ASH 2024 meeting, held from December 7-10 in San Diego, California.
- | Tecentriq (atezolizumab) / Roche
Journal: Large vessel vasculitis associated with atezolizumab. (Pubmed Central) - Apr 27, 2025
Although large vessel vasculitis was reported in one patient who had received both atezolizumab and pegfilgrastim, our patient represents the first instance of large vessel vasculitis associated with atezolizumab alone. Discontinuation of atezolizumab and tapered glucocorticoid therapy resulted in clinical and radiographic resolution.
- ||| Prolia (denosumab) / Amgen
Clinical guideline, Journal: Update of the recommendations for the management and treatment of giant cell bone tumors, on behalf of GroupOS (Pubmed Central) - Apr 27, 2025
Rarely, GCTs undergo malignant transformation. No clinical, histological or radiographic criteria can accurately predict subsequent aggressive behaviour.
- || CM326 / Keymed Biosciences, Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
P1 data, Preclinical, Journal: Translational Investigation of CM326 from Preclinical Studies to Randomized Phase I Clinical Trials in Healthy Adults. (Pubmed Central) - Apr 27, 2025
P1
No clinical, histological or radiographic criteria can accurately predict subsequent aggressive behaviour. CM326 improved Th2 inflammation preclinically and demonstrated an acceptable safety profile with linear pharmacokinetics and low immunogenicity in healthy adults.
- | Lumakras (sotorasib) / Amgen
Journal: Oncogenic KRAS addiction states differentially influence MTH1 expression and 8-oxodGTPase activity in lung adenocarcinoma. (Pubmed Central) - Apr 26, 2025
Conversely, KRAS depletion or its inhibition by AMG-510 (sotorasib) decreased MTH1 in KRASG12C-addicted LUAD cells...Our studies suggest that despite loss of KRAS dependency, LUAD cells retain the requirement for high MTH1 8-oxodGTPase activity due to redox vulnerabilities associated with AKT signaling. Thus, MTH1 may serve as a novel orthogonal vulnerability in LUAD that has lost KRAS addiction.
- | ivabradine / Generic mfg.
Journal: Ivabradine exposures reported to United States poison centers 2015-2023. (Pubmed Central) - Apr 26, 2025
Adults with unintentional, asymptomatic exposures to ivabradine may be candidates for home monitoring. In ivabradine exposures refractory to medical management, clinicians should consider cardiac pacing or other supportive measures as a temporizing measure.
- ||| Lonsurf (trifluridine/tipiracil) / Otsuka
Enrollment open: TRIFLUOX-DP: Safety of Trifluridine/Tipiracil in Patients With Dihydropyrimidine Dehydrogenase Deficiency Diagnosed With Metastatic Colorectal or Gastroesophageal Cancer (clinicaltrials.gov) - Apr 26, 2025
P2, N=73, Recruiting, Sponsor: UNICANCER
In ivabradine exposures refractory to medical management, clinicians should consider cardiac pacing or other supportive measures as a temporizing measure. Not yet recruiting --> Recruiting
- | Truxima (rituximab-abbs) / Indukern, Teva, Mundipharma, Celltrion, Nippon Kayaku, Neupogen (filgrastim) / Kyowa Kirin, Amgen, Rituxan (rituximab) / Roche
Trial completion date: NCI-2011-00344: Genetically Engineered Lymphocyte Therapy After Peripheral Blood Stem Cell Transplant in Treating Patients With High-Risk, Intermediate-Grade, B-cell Non-Hodgkin Lymphoma (clinicaltrials.gov) - Apr 26, 2025
P1/2, N=8, Active, not recruiting, Sponsor: City of Hope Medical Center
Not yet recruiting --> Recruiting Trial completion date: Mar 2025 --> Feb 2026
- ||||| namilumab (IZN-101) / Amgen, Izana Biosci, Roivant
Trial termination: RESOLVE-Lung: A Study to Assess the Efficacy and Safety of Namilumab in Participants With Chronic Pulmonary Sarcoidosis (clinicaltrials.gov) - Apr 25, 2025
P2, N=107, Terminated, Sponsor: Kinevant Sciences GmbH
Trial completion date: Mar 2025 --> Feb 2026 Active, not recruiting --> Terminated; Sponsor Decision
- | topotecan / Generic mfg.
New P1 trial: Pilot Study of IT Topotecan and Maintenance Chemotherapy for HR-EBTs in Children < 6 Years, Post Consolidation (clinicaltrials.gov) - Apr 25, 2025
P1, N=15, Not yet recruiting, Sponsor: C17 Council
- || vociprotafib (RMC-4630) / Revolution Medicines
Trial completion, Trial completion date, Trial primary completion date: RMC-4630-03: Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies (clinicaltrials.gov) - Apr 25, 2025
P2, N=47, Completed, Sponsor: Revolution Medicines, Inc.
Active, not recruiting --> Terminated; Sponsor Decision Active, not recruiting --> Completed | Trial completion date: Mar 2024 --> Aug 2024 | Trial primary completion date: Sep 2023 --> Jul 2024
- | Imdelltra (tarlatamab-dlle) / Amgen
New P3 trial: TARLANEC: Tarlatamab vs Standard of Care Chemotherapy in Patients With Pre-treated Advanced, Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Carcinomas (NECs) (clinicaltrials.gov) - Apr 24, 2025
P3, N=129, Not yet recruiting, Sponsor: Intergroupe Francophone de Cancerologie Thoracique
- | Prolia (denosumab) / Amgen, Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
New P4 trial: Effects of Cycle Therapy vs Sequential Therapy With Romosozumab and Denosumab in Postmenopausal Osteoporosis Patients (clinicaltrials.gov) - Apr 24, 2025
P4, N=70, Recruiting, Sponsor: National Taiwan University Hospital
- Imdelltra (tarlatamab-dlle) / Amgen
Tarlatamab-induced immune-related adverse events: Retrospective real-world pharmacovigilance study using FAERS database. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_7278;
(8% in thevs 0% in the clinical trial). This may reflect a broader selection of patients in real-world settings.
- Prolia (denosumab) / Amgen
Application of N-terminal telopeptide of type I collagen in the evaluation of bone metastasis degree and efficacy. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_7193;
uCr-corrected uNTX excretion rates can effectively reflect the severity and treatment response of bone metastases and have the potential to serve as a convenient auxiliary tool for the clinical management of patients with bone metastases. Combining uNTX measurements with traditional imaging examinations can further improve the assessment system for bone metastasis status and treatment efficacy.
- Stivarga (regorafenib) / Bayer
The efficacy and safety of radiotherapy combined with tyrosine kinase inhibitors in the treatment of advanced GIST. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_7189;
P1/2
Advanced GIST patients benefit frequently from radiotherapy. The model of radiotherapy combined with TKI in the treatment of advanced GIST patients deserves further exploration.
- Prolia (denosumab) / Amgen
Malignant giant cell tumor of bone: A case series in the denosumab era. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_7166;
The prognosis is poor despite local only relapse after a previous GCTB and aggressive treatments. Accurate diagnosis is critical to avoid delayed treatment.
- Imlygic (talimogene laherparepvec) / Amgen, Yondelis (trabectedin) / PharmaMar, J&J, Opdivo (nivolumab) / Ono Pharma, BMS
Phase 2 study using talimogene laherparepvec, nivolumab, and trabectedin for advanced leiomyosarcoma and liposaroma (NCT03886311). () - Apr 23, 2025 - Abstract #ASCO2025ASCO_7153;
P2
Taken together, the results indicate that the combination regimen of Talimogene laherparepvec, Nivolumab, and Trabectedin may be more effective than Trabectedin alone (Median PFS 4.1 months) as treatment for previously treated patients with advanced leiomyosarcoma and liposarcoma with manageable toxicity. A randomized phase 2 clinical trial is warranted to confirm these promising results.
- Imdelltra (tarlatamab-dlle) / Amgen
Optimizing tarlatamab therapy for relapsed small cell lung cancer: Biomarker identification and addressing treatment delivery disparity. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_7058;
By improving outcomes for underserved populations, this approach also offers a model for broader implementation of T-cell engager therapies. This study is supported by the Ride Hard Breathe Easy Foundation, Philadelphia.
- Lonsurf (trifluridine/tipiracil) / Otsuka, Fruzaqla (fruquintinib) / Takeda, Stivarga (regorafenib) / Bayer
Real-world evidence of fruquintinib (Fruq) efficacy after regorafenib (Rego) and trifluridine () - Apr 23, 2025 - Abstract #ASCO2025ASCO_7055;
The data suggest flexibility in treatment choices, with Fruquintinib showing improved OS when used earlier in the treatment sequence. These findings underscore the importance of exploring optimal sequencing strategies and evaluating Fruquintinib as a potential option before other approved agents in the refractory setting.
- Ibrance (palbociclib) / Pfizer, Keytruda (pembrolizumab) / Merck (MSD), Herceptin (trastuzumab) / Roche
"How much does your medication cost?": Assessing patient attitudes towards the costs of oncology medication to society. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_7026;
This study provides an insight into Irish breast cancer patient attitudes towards societal oncology drug costs. These findings indicate that Irish breast cancer patients find the societal costs of many commonly prescribed oncology medications to be unacceptable and that many of these patients have a desire to be better informed of these costs.
- Tumor-agnostic therapies in a high-volume Brazilian center: Real-world challenges and opportunities. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_7013;
The analysis was limited by unmatched distribution of tumor types, lacking treatment history and comorbidities among groups. Limited access to TAT may reflect the timing of tests, pre-dating some agnostic approvals, as well as the high cost and restricted availability of these therapies.
- Unexplored targets in myeloid neoplasms: Investigating potential areas of clinical actionability using a comprehensive genomic database. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_6985;
Our findings identify actionable mutations in MNs (KRAS, EZH2, NF1, BRAF) with FDA-approved targeted therapies (e.g. sotorasib, tazemetostat, selumetinib, vemurafenib). These mutations are underexplored in MNs, though some studies have assessed MEK inhibitors for certain subtypes.
- Assessing the risk of cytokine release syndrome associated with the use of antineoplastic agents: A real-world pharmacovigilance study based on the FDA Adverse Event Reporting System database (FAERS). () - Apr 23, 2025 - Abstract #ASCO2025ASCO_6830;
Traditional chemotherapy agents, though sometimes implicated in CRS, displayed lower signals, while corticosteroids showed the weakest association, consistent with their role in CRS management. These findings reinforce the importance of continued pharmacovigilance efforts to optimize the safety of emerging immunotherapies in oncology.
- Stivarga (regorafenib) / Bayer
Tyrosine kinase inhibitors in children and adolescents with recurrent/refractory sarcomas. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_6707;
Our real-world data suggest that TKI may be effective in RR sarcomas with acceptable toxicities. Inclusion of TKIs in earlier lines of treatment and/or maintenance therapy could be questions for future research.
- Imlygic (talimogene laherparepvec) / Amgen, Keytruda (pembrolizumab) / Merck (MSD), Opdivo (nivolumab) / Ono Pharma, BMS
Systemic therapies for advanced melanoma after immunotherapy failure: Efficacy and safety insights. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_6639;
Heterogeneity of study designs, response rates, and toxicity profiles complicate direct comparisons. Given the high efficacy, TIL therapy and TVEC should be considered as second line treatment options.
- Imlygic (talimogene laherparepvec) / Amgen
Retrospective study of unresectable stage III or stage IV melanoma refractory to immune checkpoint and BRAF/MEK inhibitors, treated with triplet vs doublet therapy: A single institution experience. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_6632;
months in doublet therapy arm (p=0.8143). mPFS in triplet and doublet therapy arm is 7.5 months and 10.8 months respectively.
- Molecular profiling using NGS in lung cancer patients: Revolutionizing targeted therapy and personalized treatment. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_6533;
The findings described above underline the necessity of a multigene analysis for patients with NSCLC, in order to benefit from the available targeted therapies. PDL-1 testing increases this benefit as it is a positive predictive biomarker for immunotherapy, even for patients harboring no driver mutations.
- Krazati (adagrasib) / BMS, Lumakras (sotorasib) / Amgen
Outcomes with KRAS G12C inhibitors in metastatic non-small cell cancer: A systematic review and meta-analysis. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_6522;
KRAS G12C inhibitors displayed favorable efficacy with acceptable safety profile in the 2nd of later line of therapies. It is the need of an hour to study this targeted therapy in the first line in mNSCLC patients.
- Efficacy and safety of KRAS p.G12C inhibitors in advanced NSCLC: A systematic review and meta-analysis. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_6512;
This meta-analysis underscores the favorable safety and efficacy profiles of KRAS p.G12C inhibitors after first-line progression in advanced NSCLC, despite the frequent adverse events, which were considered manageable. Further randomized controlled trials are expected to confirm these results and refine their role in subgroup populations, including STK1 and KEAP1 co-mutations, that confer even poor prognosis.
- AMG 119 / Amgen
A systematic review of CAR T-cell therapy in lung cancer: Move forward or move on? () - Apr 23, 2025 - Abstract #ASCO2025ASCO_6461;
P1, P1/2
The best response has been PR in < 10% of reported patients; this is not encouraging, but the details of individual patients are unclear for a meta-analysis. The results of ongoing clinical trials will be important to inform the direction of future investigations.
- Lumakras (sotorasib) / Amgen
Chemotherapy versus targeted therapy in high and low NRF2 lung adenocarcinoma. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_6379;
These changes were attenuated post chemotherapy. Further, high growth inhibition was observed with carboplatin treatment in NRF2low and NRF2high LUAD cells compared to sotorasib.
- Imdelltra (tarlatamab-dlle) / Amgen
Real-world safety and efficacy of tarlatamab in patients with small cell lung cancer or extrapulmonary small cell carcinoma. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_6367;
However, median PFS and OS were notably shorter, likely due to the small sample size and the inclusion of pts with poor prognostic factors like oxygen use, poor ECOG status, and untreated CNS mets. The higher incidence of CRS and ICANS following C1D1 highlights the need for vigilant monitoring during initial cycles.
- Zepzelca (lurbinectedin) / PharmaMar, Jazz
Real-world effectiveness of lurbinectedin in extensive stage small cell lung cancer (ES-SCLC). () - Apr 23, 2025 - Abstract #ASCO2025ASCO_6343;
If the median TTD can be considered a potential surrogate for progression free survival (PFS), then we would have a PFS of 3 months which is slightly shorter in our cohort compared to 3.5 months reported by Trigo et al in their original paper. Retrospective nature of the study and lack of control group, however, limit the predictor variables.
- Prolia (denosumab) / Amgen
Comparative efficacy and safety of bisphosphonates and other bone-modifying agents in patients with bone metastases from lung cancer: A systematic review and Bayesian network meta-analysis. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_6324;
Zoledronic Acid and Ibandronate showed moderate efficacy with favorable safety profiles. These findings provide evidence-based guidance for selecting optimal BMAs and supporting clinical decision-making in this patient population.
- Imdelltra (tarlatamab-dlle) / Amgen
Real world outcomes of patients treated with tarlatamab in extensive stage small cell lung cancer. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_6303;
The association between presence of CNS metastatic disease, prior CNS radiation and incidence of ICANS needs to be explored further. Mayo Clinic report of tarlatamab real world outcomes and toxicity.
- Blincyto (blinatumomab) / Astellas, Amgen, Besponsa (inotuzumab ozogamicin) / Pfizer
Unmet need in adults and adolescents and young adults (AYAs) with B-cell acute lymphoblastic leukemia (B-ALL) in the US following a second relapse. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_6078;
Half of adults and AYAs with B-ALL who received 1L treatment went on to require 3L treatment. The majority (76%) of patients requiring 3L treatment were AYAs and adults aged 41
- Chemoinduction therapy and its response in Jehovah's Witnesses with acute lymphoblastic leukemia: A systematic review. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_6063;
The myelosuppressive effects of chemo-induction, in the absence of blood and blood-product transfusions, present a substantial clinical challenge, supportive agents allow us to counteract this to a considerable degree. Careful supportive management enables remission, though long-term survival remains uncertain.
- Blincyto (blinatumomab) / Astellas, Amgen
Cytokine release syndrome among acute lymphocytic leukemia adults undergoing treatment with blinatumomab in the United States. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_6039;
The most common form of CRS was grade 1, while grade 2 involved an older group. Furthermore, we confirmed that CRS significantly impacted the healthcare burden among such admissions.
- Ibrance (palbociclib) / Pfizer
Palbociclib in patients (pts) with ovarian cancer (OC) with CDKN2A alterations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_5766;
P2
Additional study is warranted to confirm the efficacy of palbociclib in this pt population. Demographics and Efficacy Outcomes (N=28)
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, Vectibix (panitumumab) / Amgen
Comprehensive clinical and genomic characterization of advanced urachal and non-urachal adenocarcinomas of the urinary tract. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_5556;
Non-5-FU based chemo shows more activity in NUA, aligning genomically with urothelial cancer. The prognostic value of KRAS alterations and the role of KRAS as a promising therapeutic target in UA, genomically resembling colorectal cancer, merits further study.
- Stivarga (regorafenib) / Bayer, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Efficacy and safety of regorafenib combined with immune checkpoint inhibitors in advanced hepatocellular carcinoma patients progressing after lenvatinib treatment. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_5498;
Regorafenib combined with ICIs demonstrates promising efficacy and acceptable safety in patients with advanced HCC who have progressed after lenvatinib treatment. This study provides reference data that may inform clinical treatment choices for this patient population.